drugset / Trial / NCT00322621

Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

NCT00322621 ↗

Phase 4 Completed 216 enrolled Eli Lilly and Company Boehringer Ingelheim · collab
NaSingle-groupOpen-labelTreatment

Summary

To determine if duloxetine 60 mg once daily can work up to 6 months in treating pain from Diabetic Neuropathy.

Timeline

Start
2006-04
Primary completion
2007-10
Completion
2007-10

Outcome

Met primary endpoint

paper 0.79 as the upper bound of the one-sided 97.5% CI, which was less than the pre-specified non-inferiority margin of 1.5 (p < 0.001). PMID 19637208 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg Oral
Subject Duloxetine Small molecule 120 mg Oral

Indications